PLI PLUS Title Details

Skip to main content

Create Account
Training Center
Contact Us

Questions? Comments?
Contact us.

Email: PLUS@pli.edu
Phone: 877.900.5291
PLI.edu
SIGN IN

Search
Browse
My Bookshelf
My History

< Back To Results

1 in 1 results

Previous Result
Next Result

Book Cover Image

Trial by Jury 2016

Chair(s): David R. Marriott

Practice Area: Criminal litigation, Evidence, Jury trials, Litigation, Trial

Published: Nov 2016 i Other versions can be found in the Related Items tab.
ISBN: 9781402427893
PLI Item #: 150097
CHB Spine #: H1043

This version is not current.
Click here for the most recent version.

Email
Print
Add To Bookshelf
Permalink

Table of Contents
Related Items

Select All

Front Matter
Faculty Bios
Table of Contents
Chapter 1. Jury Selection: Suggestions for Picking Your Best Triers of Fact
Chapter 2. Voir Dire Preparation Skills
Chapter 3. Jury Questionnaire, United States District Court, Southern District of New York
Chapter 4. Delaware Trial Handbook § 6:7. Voir Dire and Challenges for Cause in Civil and Non-Capital Criminal Cases
Chapter 5. The Opening Statement: Charting a Path to Victory
Chapter 6. Opening Statement
Chapter 7. Novartis Pharmaceuticals Corporation, Novartis Pharma AG, and Novartis International Pharmaceutical Ltd. v. Teva Pharmaceuticals, USA, Inc., CIVIL NO. 05-CV-1887-DMC: Plaintiff’s Opening Statement by Evan R. Chesler
Chapter 8. Ventas, Inc. v. Health Care Property Investors, Inc., CASE NO. 3:07-CV-00238-H, Plaintiff’s Opening Statement by David J. Bradford
Chapter 9. Direct to Success: How to Conduct an Effective Direct Examination
Chapter 10. An In-Depth Look at Direct Examination of Expert Witnesses
Chapter 11. Direct Examination: A Forgotten Art
Chapter 12. Novartis Pharmaceuticals Corporation, Novartis Pharma AG, and Novartis International Pharmaceutical Ltd. v. Teva Pharmaceuticals, USA, Inc., CIVIL NO. 05-CV-1887-DMC: Direct Examination by David R. Marriott
Chapter 13. In Re Vivendi Universal, S.A. Securities Litigation [CIVIL ACTION NO. 02-5571]: Direct Examination by Daniel Slifkin
Chapter 14. Cross Examination: Nine Suggestions for Success
Chapter 15. Killer Cross of Fact Witnesses—Yours and Theirs
Chapter 16. Transcripts from Various Trials
Chapter 17. Delaware Trial Handbook § 14:3. Scope and Form of Cross Examination
Chapter 18. Novartis Pharmaceuticals Corporation, Novartis Pharma AG, and Novartis International Pharmaceutical Ltd. v. Teva Pharmaceuticals, USA, Inc., CIVIL NO. 05-CV-1887-DMC: Cross Examination by David R. Marriott
Chapter 19. Compuware Corporation v. International Business Machines Corporation, CASE NO. 02-CV-790906, Cross-Examination by Evan R. Chesler
Chapter 20. Ethical Limitations on Online Publicity: Weighing the Risk of Prejudicing Jurors
Chapter 21. Closing to Win: Closing Argument: Suggestions for Effective Advocacy
Chapter 22. The Art and Architecture of Closing Argument
Chapter 23. Delaware Trial Handbook § 24:2. General Rules Covering Closing Arguments in Civil and Criminal Cases
Chapter 24. Novartis Pharmaceuticals Corporation, Novartis Pharma AG, and Novartis International Pharmaceutical Ltd. v. Teva Pharmaceuticals, USA, Inc., CIVIL NO. 05-CV-1887-DMC: Plaintiff’s Closing Argument by Evan R. Chesler
Index

About Us

All Contents Copyright © 1996-2021 Practising Law Institute. About PLI PLUS PLI Librarian Blog PLI PLUS app Privacy Policy Terms Of Use
Continuing Legal Education since 1933.